Drug Profile
Research programme: galectin modulators - Galecto Biotech
Alternative Names: GAL-200; GAL-300; GAL-400; Galectin activators - Galecto; Galectin inhibitors - Galecto; Galectin-3 inhibitors - Galecto; GB-1107Latest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator Galecto Biotech
- Developer Galecto Inc
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Eye disorder therapies; Small molecules
- Mechanism of Action Galectin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Eye disorders; Fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cancer in Denmark
- 28 Mar 2023 No recent reports of development identified for preclinical development in Eye-disorders in Denmark
- 28 Mar 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Denmark